TABLE 2.

Risk of mortality (cancer‐specific survival) among the users of antihypertensive medication (PDC ≥ 80% vs. PDC < 80%). (N = 13,982)

		Hazard Ratio (95% CI)
PDC	>=80%	0.94 (0.90 to 0.98)
	<80%	Reference
Age		1.01 (1.00 to 1.01)
Sex	Male	1.07 (1.03 to 1.12)
	Female	Reference
Marital status	Single/Other	1.08 (1.03 to 1.13)
	Married	Reference
Race	Black	0.97 (0.91 to 1.05)
Race	Other	1.04 (0.98 to 1.11)
	White	Reference
Chemotherapy	No	1.07 (1.01 to 1.13)
	Yes	Reference
Surgery	No	1.39 (1.23 to 1.58)
	Yes	Reference
Stage	Stage II	0.98 (0.93 to 1.03)
	Stage III	1.00 (0.95 to 1.06)
	Stage I	Reference
Tumor grade	Moderately differentiated	1.04 (0.97 to 1.11)
	Poorly differentiated	1.05 (0.96 to 1.14)
	Undifferentiated	1.30 (1.11 to 1.51)
	Well differentiated	Reference
Metformin	Yes	1.04 (0.98 to 1.10)
	No	Reference
Diabetes	Yes	1.02 (0.96 to 1.08)
	No	Reference
CCI	1	1.08 (1.02 to 1.14)
CCI	2+	1.21 (1.14 to 1.28)
	0	Reference
Monotherapy	Yes	1.15 (1.10 to 1.20)
	No	Reference
Hypertension	Yes	1.13 (1.07 to 1.18)
	No	Reference
Cancer Type	Rectal	0.99 (0.94–1.06)
	Colon	Reference
Radiation	Yes	1.01 (0.92–1.10)
	Unknown	1.18 (0.98–1.43)
	No	Reference